Strategies to control trachoma

Drugs

Volumn 69, Issue 8, 2009, Pages 953-970

  Mathew, Anu A ^a   Turner, Angus ^b   Taylor, Hugh R ^a,b,c  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ROYAL VICTORIAN EYE AND EAR HOSPITAL   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; TETRACYCLINE;

ABDOMINAL PAIN; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BLINDNESS; CHLAMYDIA TRACHOMATIS; CORNEA OPACITY; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG METABOLISM; ENVIRONMENTAL SANITATION; HUMAN; NAUSEA; PATIENT EDUCATION; PERSONAL HYGIENE; PREVALENCE; RECURRENCE RISK; REVIEW; RISK FACTOR; TRACHOMA; TRICHIASIS; VOMITING;

ANIMALS; ANTI-BACTERIAL AGENTS; BLINDNESS; CHLAMYDIA TRACHOMATIS; DRUG RESISTANCE, BACTERIAL; FACE; HEALTH EDUCATION; HUMANS; TRACHOMA; WATER SUPPLY; WORLD HEALTH ORGANIZATION;

CHLAMYDIA TRACHOMATIS;

EID: 66949128696     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200969080-00002     Document Type: Review

References (132)

1. Taylor HR. Trachoma: a blinding scourge from the bronze age to the twenty-first century. Melbourne (VIC): Centre for Eye Research Australia, 2008
2. Mariotti SP, Pascolini D, Rose-Nussbaumer J. Trachoma: global magnitude of a preventable cause of blindness. Br J Ophthalmol. Epub 2008 Dec 19
3. World Health Organization, International Agency for the Prevention of Blindness, VISION 2020. Global initiative for the elimination of avoidable blindness, action plan 2006-2011. Geneva, World Health Organization, International Agency for the Prevention of Blindness, VISION 2020, 2007
4. Abdou A, Nassirou B, Kadri B, et al. Prevalence and risk factors for trachoma and ocular Chlamydia trachomatis infection in Niger. Br J Ophthalmol 2007; 91: 13-7
5. Courtright P, Sheppard J, Lane S, et al. Latrine ownership as a protective factor in inflammatory trachoma in Egypt. Br J Ophthalmol 1991; 75: 322-5
6. Katz J, West KP, Khatry SK, et al. Prevalence and risk factors for trachoma in Sarlahi district, Nepal. Br J Ophthalmol 1996; 80: 1037-41
7. West SK, Munoz B, Mkocha H, et al. Progression of active trachoma to scarring in a cohort of Tanzanian children. Ophthalmic Epidemiol 2001; 8: 137-44
8. Guzey M, Ozardali I, Basar E, et al. A survey of trachoma: the histopathology and the mechanism of progressive cicatrization of eyelid tissues. Ophthalmologica 2000; 214 (4): 277-84
9. Bowman RJ, Jatta B, Cham B, et al. Natural history of trachomatous scarring in the Gambia: results of a 12-year longitudinal follow-up. Ophthalmology 2001; 108 (12): 2219-24
10. Marx R. Social factors and trachoma: a review of the literature. Soc Sci Med 1989; 29 (1): 23-34
11. Polack S, Brooker S, Kuper H, et al. Mapping the global distribution of trachoma. Bull World Health Org 2005; 83: 913-9
12. Luna EJA, Medina NH, Oliveira MB, et al. Epidemiology of trachoma in Bebedouro State of Sao Paulo, Brazil: prevalence and risk factors. Int J Epidemiol 1992; 21 (1): 169-77
13. Hsieh Y, Bobo LD, Quinn TC, et al. Risk factors for trachoma: 6-year follow-up. Am J Epidemiol 2000; 152 (3): 204-11
14. Taylor HR, West S, Mmbaga BBO, et al. Hygiene factors and increased risk of trachoma in central Tanzania. Arch Ophthalmol 1989; 107: 1821-5
15. Wright HR, Turner A, Taylor HR. Trachoma. Lancet 2008; 371: 1945-54
16. Patton DL, Wang SK, Kuo CC. The activity of azi-thromycin on the infectivity of Chlamydia trachomatis in human amniotic cells. J Antimicrob Chemother 1995; 36 (6): 951-9
17. Beatty WL, Morrison RP, Byrne GI. Persistent chlamydiae-from cell-culture to a paradigm for chlamydial pathogenesis. Microbiol Rev 1994; 58 (4): 686-99
18. World Health Organization, London School of Hygiene & Tropical Medicine, International Trachoma Initiative. Trachoma control: a guide for programme managers. Geneva: World Health Organization, London School of Hygiene & Tropical Medicine, International Trachoma Initiative, 2006
19. Mariotti SP, Pararajasegaram R, Resnikoff S. Trachoma: looking forward to global elimination of trachoma by 2020 (GET 2020). Am J Trop Med Hyg 2003; 69: 33-5
20. Lietman TM, Fry A. Can we eliminate trachoma. Br J Ophthalmol 2001; 85: 385-7
21. Emerson PM, Cairncross S, Bailey RL, et al. Review of the evidence base for the 'F' and 'E' components of the SAFE strategy for trachoma control. Trop Med Int Health 2000; 5 (8): 515-27
22. Reacher MH, Munoz B, Alghassany A, et al. A controlled trial of surgery for trachomatous trichiasis of the upper lid. Arch Ophthalmol 1992; 110 (5): 667-74
23. Reacher M, Foster A, Huber J. Trichiasis surgery for trachoma: the bilamellar tarsal rotation procedure. Geneva: World Health Organization, 1993. Report no. WHO/ PBL/93.29
24. Thanh TTK, Khandekar R, Luong VQ, et al. One year recurrence of trachomatous trichiasis in routinely operated Cuenod Nataf procedure cases in Vietnam. Br J Ophthalmol 2004; 88 (9): 1114-8
25. West SK, Bedri A, Thanh TTK, et al. Final assessment of trichiasis surgeons. Geneva: World Health Organization; 2005. Report no. WHO/PBD/GET/05.2
26. Bog H, Yorston D, Foster A. Results of community-based eyelid surgery for trichiasis due to trachoma. Br J Ophthalmol 1993; 77 (2): 81-3
27. Zhang H, Kandel RP, Sharma B, et al. Risk factors for recurrence of postoperative trichiasis: implications for trachoma blindness prevention. Arch Ophthalmol 2004; 122 (4): 511-6
28. West ES, Mkocha H, Munoz B, et al. Risk factors for postsurgical trichiasis recurrence in a trachoma-endemic area. Invest Ophthalmol Vis Sci 2005; 46 (2): 447-53
29. Merbs SL, West SK, West ES. Pattern of recurrence of trachomatous trichiasis after surgery surgical technique as an explanation. Ophthalmology 2005; 112 (4): 705-9
30. Burton MJ, Bowman RJC, Faal H, et al. Long term outcome of trichiasis surgery in the Gambia. Br J Ophthalmol 2005; 89 (5): 575-9
31. Burton MJ, Kinteh F, Jallow O, et al. A randomised controlled trial of azithromycin following surgery for trachomatous trichiasis in the Gambia. Br J Ophthalmol 2005; 89 (10): 1282-8
32. Zhang H, Kandel RP, Atakari HK, et al. Impact of oral azithromycin on recurrence of trachomatous tri-chiasis in Nepal over 1 year. Br J Ophthalmol 2006 Aug; 90 (8): 943-8
33. West SK, West ES, Alemayehu W, et al. Single-dose azithromycin prevents trichiasis recurrence following surgery: randomized trial in Ethiopia. Arch Ophthalmol 2006; 124 (3): 309-14
34. Rabiu MM, Abiose A. Magnitude of trachoma and barriers to uptake of lid surgery in a rural community of northern Nigeria. Ophthalmic Epidemiol 2001; 8 (2-3): 181-90
35. Bowman RJC, Faal H, Jatta B, et al. Longitudinal study of trachomatous trichiasis in the Gambia: barriers to acceptance of surgery. Invest Ophthalmol Vis Sci 2002; 43 (4): 936-40
36. Burton MJ, Bowman RJC, Faal H, et al. The long-term natural history of trachomatous trichiasis in the Gambia. Invest Ophthalmol Vis Sci 2006; 47 (3): 847-52
37. Nagpal G, Dhaliwal U, Bhatia MS. Barriers to acceptance of intervention among patients with trachomatous trichiasis or entropion presenting to a teaching hospital. Ophthalmic Epidemiol 2006; 13 (1): 53-8
38. Bowman RJ, Soma OS, Alexander N, et al. Should trichiasis surgery be offered in the village? A community randomised trial of village vs health centre-based surgery. Trop Med Int Health 2000; 5 (8): 528-33
39. Mahande M, Tharaney M, Kirumbi E, et al. Uptake of trichiasis surgical services in Tanzania through two village-based approaches. Br J Ophthalmol 2007 Feb; 91 (2): 139-42
40. Lewallen S, Mahande M, Tharaney M, et al. Surgery for trachomatous trichiasis: findings from a survey of trichiasis surgeons in Tanzania. Br J Ophthalmol 2007 Feb; 91 (2): 143-5
41. Dhaliwal U, Bhatia M. Health-related quality of life in patients with trachomatous trichiasis or entropion. Ophthalmic Epidemiol 2006; 13: 59-66
42. Baltussen RM, Sylla M, Frick KD, et al. Cost-effectiveness of trachoma control in seven world regions. Ophthalmic Epidemiol 2005; 12 (2): 91-101
43. Baltussen R, Sylla M, Mariotti SP. Cost-effectiveness analysis of cataract surgery: a global and regional analysis. Bull World Health Org 2004; 82 (5): 338-45
44. Dawson CR, Daghfous T, Whitcher J, et al. Intermittent trachoma chemotherapy: a controlled trial of topical tetracycline or erythromycine. Bull World Health Org 1981; 59 (1): 91-7
45. Sanchez AR, Rogers RS, Sheridan PJ. Tetracycline and other tetracycline-derivative staining of the teeth and oral cavity. Int J Dermatol 2004; 43 (10): 709-15
46. Maitchouk IF. Report of blindness in the Middle East. Cairo: Regional Office for the Eastern Mediterranean, World Health Organization, 1976 Mar. Report no.: EM/ICP/VIR/001/RB
47. Schachter J, West SK, Mabey D, et al. Azithromycin in control of trachoma. Lancet 1999 Aug; 354 (9179): 630-5
48. Bailey RL, Arullendran P, Whittle HC, et al. Randomised controlled trial of single-dose azithromycin in treatment of trachoma. Lancet 1993 Aug; 342 (8869): 453-6
49. Taylor HR. Report of a workshop: research priorities for the control of trachoma. J Infect Dis 1985; 152 (2): 383-8
50. Hoepelman IM, Schneider MM. Azithromycin: the first of the tissue-selective azalides. Int J Antimicrob Agents 1995; 5 (3): 145-67
51. Pfizer Inc. Zithromax (azithromycin tablets) and (azithromycin for oral suspension) 70-5179-00-4. Product Insert 2004; 70: 1-32
52. Wood N, McIntyre P. Pertussis: review of epidemiology, diagnosis, management and prevention. Paediatr Respir Rev 2008 Sep; 9 (3): 201-11; quiz 11-2
53. Gray RH, Wabwire-Mangen F, Kigozi G, et al. Randomized trial of presumptive sexually transmitted disease therapy during pregnancy in Rakai, Uganda. Am J Obstet Gynecol 2001; 185 (5): 1209-17
54. 2006 UK National Guideline for the Management of Genital Tract Infection with Chlamydia trachomatis. [online]. Available from URL: http://www.bashh.org/documents/ 61/61.pdf [Accessed 2009 Apr 3]
55. Tabbara KF, AEl-Asrar AMA, Al-Omar O, et al. Single-dose azithromycin in the treatment of trachoma. Ophthalmology 1996; 103: 842-6
56. Karcioglu ZA, El-Yazigi A, Jabak MH, et al. Pharmaco-kinetics of azithromycin in trachoma patients. Ophthalmology 1998; 105: 658-61
57. Mabey D, Fraser-Hurt N. Antibiotics for trachoma. Cochrane Database Syst Rev 2005; (2): CD001860
58. Wright HR, Keeffe JE, Taylor HR. Elimination of trachoma: are we in danger of being blinded by the randomized controlled trial. Br J Ophthalmol 2006; 90: 1339-40
59. Dawson CR, Schachter J, Sallam S, et al. A comparison of oral azithromycin with topical oxytetracycline/ polymyxine for the treatment of trachoma in children. Clin Infect Dis 1997; 24: 363-8
60. Bowman RJ, Sillah A, Van Dehn C, et al. Operational comparison of single-dose azithromycin and topical tetracycline for trachoma. Invest Ophthalmol Vis Sci 2000; 41 (13): 4074-9
61. Fraser-Hurt N, Bailey RL, Cousens S, et al. Efficacy of oral azithromycin versus topical tetracycline in mass treatment of endemic trachoma. Bull World Health Org 2001; 79: 632-40
62. Chidambaram JD, Alemayehu W, Melese M, et al. Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma. JAMA 2006 Mar; 295 (10): 1142-6
63. Solomon AW, Holland MJ, Alexander NDE, et al. Mass treatment with single-dose azithromycin for trachoma. N Engl J Med 2004 Nov; 351 (19): 1962-71
64. Solomon AW, Harding-Esch E, Alexander NDE, et al. Two doses of azithromycin to eliminate trachoma in a Tanzanian community. N Engl J Med 2008 Apr; 358 (17): 1870-1
65. Melese M, Chidambaram JD, Alemayehu W, et al. Feasibility of eliminating ocular Chlamydia trachomatis with repeat mass antibiotic treatments. JAMA 2004 Aug; 292 (6): 721-5
66. West S, Munoz BE, Mkocha H, et al. Infection with Chlamydia trachomatis after mass treatment of a trachoma hyperendemic community in Tanzania: a longitudinal study. Lancet 2005; 366: 1296-300
67. International Trachoma Initiative 2008 [online]. Available from URL: http://www.trachoma.org [Accessed 2009 Apr 3]
68. Emerson P, Burton M, Solomon AW, et al. The SAFE strategy for trachoma control: using operational research for policy, planning and implementation. Bull World Health Org 2006; 84 (8): 613-9
69. World Health Organization, editor. Report of the Twelfth Meeting of the World Health Organization Alliance for the Global Elimination of Trachoma; 2008 Apr 28-30; Geneva
70. Cochereau I, Goldschmidt P, Goepogui A, et al. Efficacy and safety of short duration azithromycin eye drops versus azithromycin single oral dose for the treatment of trachoma in children: a randomised, controlled, double-masked clinical trial. Br J Ophthalmol 2007 May; 91 (5): 667-72
71. Kuper H, Wormald R. Topical azithromycin: new evidence? Br J Ophthalmol 2007; 91 (5): 566-7
72. Frick KD, Lietman TM, Holm SO, et al. Cost-effectiveness of trachoma control measures: comparing targeted household treatment and mass treatment of children. Bull World Health Org 2001; 79 (3): 201-7
73. West SK, Munoz B, Mkocha H, et al. Trachoma and ocular Chlamydia trachomatis were not eliminated three years after two rounds of mass treatment in a trachoma hyperendemic village. Invest Ophthalmol Vis Sci 2007; 48 (4): 1492-7
74. West ES, Munoz B, Mkocha H, et al. Mass treatment and the effect on the load of Chlamydia trachomatis infection in a trachoma-hyperendemic community. Invest Ophthalmol Vis Sci 2005; 46 (1): 83-7
75. Burton M, Holland MJ, Faal N, et al. Which members of a community need antibiotics to control trachoma? Conjunctival Chlamydia trachomatis infection load in gambian villages. Invest Ophthalmol Vis Sci 2003; 44 (10): 4215-22
76. Bird M, Dawson CR, Schachter JS, et al. Does the diagnosis of trachoma adequately identify ocular chlamydial infection in trachoma-endemic areas? J Infect Dis 2003 May; 187 (10): 1669-73
77. Tielsch JM, West KP, Katz J, et al. The epidemiology of trachoma in southern Malawi. Am J Trop Med Hyg 1988; 38 (2): 393-9
78. Taylor HR, Velasco FM, Sommer A. The ecology of trachoma: an epidemiological study in southern Mexico. Bull World Health Org 1985; 63 (3): 559-67
79. West S, Rapoza PE, Munoz BE, et al. Epidemiology of ocular chlamydial infection in a trachoma-hyperendemic area. J Infect Dis 1991; 163: 752-6
80. Broman AT, Shum K, Munoz B, et al. Spatial clustering of ocular chlamydial infection over time following treatment, among households in a village in Tanzania. Invest Ophthalmol Vis Sci 2006; 47 (1): 99-104
81. Holm SO, Jha HC, Bhatta RC, et al. Comparison of two azithromycin distribution strategies for controlling trachoma in Nepal. Bull World Health Org 2001; 79 (3): 194-200
82. Schemann JF, Guinot C, Traore L, et al. Longitudinal evaluation of three azithromycin distribution strategies for treatment of trachoma in a sub-Saharan African country, Mali. Acta Trop 2007 Jan; 101 (1): 40-53
83. Shelby-James TM, Leach AJ, Carapetis JR, et al. Impact of single dose azithromycin on group A streptococci in the upper respiratory tract and skin of Aboriginal children. Pediatr Infect Dis J 2002; 21 (5): 375-80
84. Fry AM, Jha HC, Lietman TM, et al. Adverse and beneficial secondary effects of mass treatment with azithromycin to eliminate blindness due to trachoma in Nepal. Clin Infect Dis 2002 Aug; 35 (4): 395-402
85. Chidambaram JD, Melese M, Alemayehu W, et al. Mass antibiotic treatment and community protection in trachoma control programs. Clin Infect Dis 2004 Nov; 39 (9): e95-7
86. House JI, Ayele B, Porco TC, et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster-randomised trial. Lancet 2009; 373: 1111-8
87. Solomon AW, Holland MJ, Burton MJ, et al. Strategies for control of trachoma: observational study with quantitative PCR. Lancet 2003; 362: 198-204
88. Taylor HR, Siler JA, Mkocha HA, et al. The natural history of endemic trachoma: a longitudinal study. Am J Trop Med Hyg 1992; 46 (5): 552-9
89. Abbott Laboratories. Erythromycin. [online]. Available from URL: http://www.rxabbott.com/pdf/erythromycin.pdf [Accessed 2009 Apr 3]
90. Tiwari T, Murphy TV, Moran J; National Immunization Program, CDC. Recommended antimicrobial agents for the treatment and postexposure prophylaxis of pertussis: 2005 CDC Guidelines. MMWR Recomm Rep 2005; 54: 1-16
91. Centre for Disease Control. CDC guidelines for management of trachoma in the northern territory (draft). Darwin (NT): Centre for Disease Control, 2008
92. Congdon N, West S, Vitale S, et al. Exposure to children and risk of active trachoma in Tanzanian women. Am J Epidemiol 1993; 137 (3): 366-72
93. Taylor HR. Misleading titles cause confusion [letter]. Arch Ophthalmol 2009; 127 (2): 225
94. Burton MJ, Holland MJ, Makalo P, et al. Re-emergence of Chlamydia trachomatis infection after mass antibiotic treatment ofa trachoma-endemic Gambian community: a longitudinal study. Lancet 2005 Apr; 365 (9467): 1321-8
95. Lietman T, Porco T, Dawson C, et al. Global elimination of trachoma: how frequently should we administer mass chemotherapy? Nat Med 1999; 5 (5): 572-6
96. Melese M, Alemayehu W, Lakew T, et al. Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA 2008 Feb; 299 (7): 778-84
97. Su H, Morrison R, Messer R, et al. The effect of doxycycline treatment and the development of protective immunity in a murine model of chlamydial genital infection. J Infect Dis 1999; 180 (4): 1252-8
98. Brunham RC, Pourbohloul B, Mak S, et al. The unexpected impact of a Chlamydia trachomatis infection control program on susceptibility to reinfection. J Infect Dis 2005; 192 (10): 1836-44
99. Dicker LW, Mosure DJ, Levine WC, et al. Impact of switching laboratory tests on reported trends in Chlamydia trachomatis infections. Am J Epidemiol 2000; 151 (4): 430-5
100. Ray KJ, Porco TC, Hong KC, et al. A rationale for continuing mass antibiotic distributions for trachoma. BMC Infect Dis 2007 Aug; 7: 91
101. Wright HR, Taylor HR. Clinical examination and laboratory tests for estimation of trachoma prevalence in a remote setting: what are they really telling us? Lancet Infect Dis 2005; 5: 313-20
102. Davies PO, Ridgway GL. The role of polymerase chain reaction and ligase chain rection for the detection of Chlamydia trachomatis. Int J STD AIDS 1997; 8: 731-8
103. Bailey RL, Hampton TJ, Hayes LJ, et al. Polymerase chain reaction for the detection of ocular Chlamydial infection in trachoma-endemic communities. J Infect Dis 1994; 170: 709-12
104. Taylor HR, Johnson SL, Prendergast RA, et al. An animal model of trachoma: II. The importance of repeated reinfection. Invest Ophthalmol Vis Sci 1982; 23 (4): 507-15
105. Michel C-EC, Solomon AW, Magbanua JPV, et al. Field evaluation of a rapid point-of-care assay for targeting antibiotic treatment for trachoma control: a comparative study. Lancet 2006 May; 367 (9522): 1585-90
106. Solomon AW, Foster A, Mabey DCW. Clinical examination versus Chlamydia trachomatis assays to guide antibiotic use in trachoma control programmes. Lancet Infect Dis 2006; 6 (1): 5-6
107. Atik B, Thanh TTK, Luong VQ, et al. Impact of annual targeted treatment on infectious trachoma and susceptibility to reinfection. JAMA 2006 Sep; 296 (12): 1488-97
108. Mabey D, Solomon AW. Mass antibiotic administration for eradication of ocular Chlamydia trachomatis. JAMA 2008 Feb; 299 (7): 819-21
109. Ridgway GL, editor. Antibiotic resistance in human chlamydial infection: should we be concerned? Tenth International Symposium on Human Chlamydial Infections; 2002 Jun 16-21; Antalya
110. Schiedler V, Bhatta RC, Miao Y, et al. Pattern of antibiotic use in a trachoma-endemic region of Nepal: implications for mass azithromycin distribution. Ophthalmic Epidemiol 2003; 10 (1): 31-6
111. Leach AJ, Shelby-James TM, Mayo M, et al. A prospective study of the impact of community-based azithromycin treatment of trachoma on carriage and resistance of Streptococcus pneumoniae. Clin Infect Dis 1997; 24 (3): 356-62
112. Chern KC, Shreshta B, Cevallos V, et al. Alterations in the conjunctival bacterial flora following a single dose of azithromycin in a trachoma endemic area. Br J Ophthalmol 1999; 83: 1332-5
113. Gaynor BD, Chidambaram JD, Cevallos V, et al. Topical ocular antibiotics induce bacterial resistance at extraocular sites. Br J Ophthalmol 2005; 89 (9): 1097-9
114. Hyde TB, Gay K, Stephens DS, et al. Macrolide resistance among invasive Streptococcus pneumoniae isolates. JAMA 2001 Oct; 286 (15): 1857-62
115. Schemann JF, Guinot C, Ilboudo L, et al. Trachoma, flies and environmental factors in Burkina Faso. Trans R Soc Trop Med Hyg 2003; 97: 63-8
116. Schemann JF, Sacko D, Malvy D, et al. Risk factors for trachoma in Mali. Int J Epidemiol 2002; 31: 194-201
117. Cumberland P, Hailu G, Todd J. Active trachoma in children aged three to nine years in rural communities in Ethiopia: prevalence, indicators and risk factors. Trans R Soc Trop Med Hyg 2005; 99 (2): 120-7
118. Mesfin MM, de la Camera J, Tareke IG, et al. A communitybased trachoma survey: prevalence and risk factors in the Tigray region of northern Ethiopia. Ophthalmic Epidemiol 2006; 13: 173-81
119. West S, Munoz B, Lynch M, et al. Impact of face-washing on trachoma in Kongwa, Tanzania. Lancet 1995 Jan; 345 (8943): 155-8
120. Cumberland P, Edwards T, Hailu G, et al. The impact of community level treatment and preventative interventions on trachoma prevalence in rural Ethiopia. Int J Epidemiol 2008 Jun; 37 (3): 549-58
121. Ngondi J, Onsarigo A, Matthews F, et al. Effect of 3 years of SAFE (surgery, antibiotics, facial cleanliness, and environmental change) strategy for trachoma control in southern Sudan: a cross-sectional study. Lancet 2006; 368: 589-95
122. Ngondi J, Matthews F, Reacher M, et al. Associations between active trachoma and community intervention with antibiotics, facial cleanliness, and environmental improvement (A,F,E). PLoS Negl Trop Dis 2008 Apr; 2 (4): E229
123. Khandekar R, Ton TKT, Do Thi P. Impact of face washing and environmental improvement on reduction of active trachoma in Vietnam: a public health intervention study. Ophthalmic Epidemiol 2006; 13 (1): 43-52
124. Mariotti SP, Pruss A. Preventing trachoma: a guide for environmental sanitation and improved hygiene. Geneva: World Health Organization, International Trachoma Initiative, 2001
125. Taylor HR. Doyne lecture: trachoma, is it history? Eye. Epub 2009 Mar 6
126. Emerson PM, Lindsay SW, Alexander N, et al. Role of flies and provision of latrines in trachoma control: clusterrandomised controlled trial. Lancet 2004; 363 (9415): 1093-8
127. Emerson P, Lindsay SW, Walraven GEL, et al. Effect of fly control on trachoma and diarrhoea. Lancet 1999; 353: 1401-3
128. West S, Emerson P, Mkocha H, et al. Intensive insecticide spraying for fly control after mass antibiotic treatment for trachoma in a hyperendemic setting: a randomized trial. Lancet 2006; 368: 596-600
129. Barreto ML, Genser B, Strina A, et al. Effect of city-wide sanitation programme on reduction in rate of childhood diarrhoea. Lancet 2007; 370 (9599): 1622-8
130. World Health Organization, editor. Declaration of Alma-Ata. International Conference on Primary Health Care; 1978 Sep 6-12 Alma-Ata, USSR. Geneva: World Health Organization, 1978
131. United Nations. UN millennium goals [online]. Available from URL: http://www.un.org/millenniumgoals [Ac-cessed 2009 Apr 3]
132. Chan M. Return to Alma-Ata. Lancet 2008 Sep; 372 (9642): 865-6